Abstract
The 90 kDa ribosomal s6 kinases (RSKs) are a group of serine/threonine kinases consisting of 4 RSK isoforms (RSK1-4), of which RSK1 is also named as p90RSK. p90RSK is directly phosphorylated and activated by its immediate upstream mediator extracellular signal-regulated kinase (Erk1/2), followed by activating various signaling pathways through phosphorylating selective downstream substrates. Aberrant induction of p90RSK has been reported in various human diseases including kidney disease suggesting a pathogenic role of p90RSK in these diseases. In response to pathogenic cues, p90RSK not only mediates intracellular signal events leading to cell-specific phenotypes but also modulates intercellular communication impacting the adjacent cellular responses. In this review, we provide an update on the current knowledge regarding the roles of p90RSK-mediated intercellular and intracellular signaling in the pathogenesis and progression of kidney diseases.
1 Introduction
The 90 kDa ribosomal s6 kinases (RSKs) are a group of serine/threonine kinases that were initially found in Xenopus to be responsible for phosphorylating ribosomal protein S6 (). There are 4 isoforms in the RSK family, including RSK1, RSK2, RSK3 and RSK4 respectively. RSK1 is also designated as p90RSK. RSK1-3 have similar expression patterns and abundance in adult tissues such as heart, brain, lung, kidney, and pancreas (). In contrast, expression of RSK4 takes place during development and its deletions are common in x-linked intellectual disability (). RSKs play important roles in the Ras-mitogen-activated protein kinase (MAPK) signaling cascade and are the direct downstream effectors of extracellular signal-regulated kinase (Erk1/2). Erk1/2 activation directly phosphorylates and activates RSKs (; ), which, in turn, activate various intracellular signaling events through selection of different phosphorylation substrates to modulate diverse cellular processes (), such as cell proliferation, survival, and motility, and/or mediate intercellular signaling relays to regulate the phenotypes of other cells.
2 Structure and activation
All RSKs share a similar structure with around 75% of which being identical. The crystal structure of human p90RSK was recently released (). These RSKs contain two functionally diverse domains: the N terminal kinase domain (NTKD) and the C terminal kinase domain (CTKD). The NTKD is part of the kinase AGC family, while the CTKD belongs to the calcium calmodulin dependent kinase (CaMK) family. Functionally, CTKD receives signals from ERK1/2 to auto-phosphorylate RSK, which is important to activate NTKD. Upon activation, NTKD will phosphorylate downstream substrates (). The CTKD and NTKD domains are bridged by a linker region about approximately 100 amino acids containing regulatory elements (). Of note, all RSKs contain an ERK1/2 docking domain facilitating their activation by ERK1/2 (). An adjacent location is also important for RSK autophosphorylation, which may play a role in ERK1/2 dissociation and subsequently RSK signal relay () (Figure 1).
FIGURE 1
Human RSKs have four conserved phosphorylation sites: Ser221, Ser363, Ser380 and Thr573 () (Figure 1). The mechanisms of RSK activation are phosphorylation site dependent. Ser221 in the NTKD is phosphorylated by phosphoinositide-dependent kinase-1 (PDK1), a constitutively active serine threonine kinase (). Ser363 and Ser380 are both located in the linker region between the two kinase domains. Ser363 is activated by ERK 1/2 phosphorylation, while Ser380 is phosphorylated by CTKD (). Notably, Ser380, when phosphorylated, also serves as a docking site for PDK1, which in turn activates Ser221 (). Thr573 in the CTKD is also phosphorylated by ERK1/2 (). Additionally, RSKs are also regulated by p38 MAPK and fibroblast growth factor receptor-3 (FGFR3). p38 MAPK has been shown to activate RSK in dendritic cells via CTKD activated by MAPK-activated kinases M2 and M3 (). FGFR3 can interact with RSK2 through tyrosine phosphorylation, which induces its activation by enhancing ERK binding ().
3 Downstream substrates
RSKs regulate diverse cellular processes through phosphorylation of selected downstream substrates from a constantly growing list. Both p90RSK (i.e. RSK1) and RSK2 have been shown to promote cell proliferation and growth (), however, it appears that they regulate distinct transcription programs of cell proliferation and growth (). p90RSK phosphorylates and inhibits GSK3β, causing the release of Cyclin D1 and cell proliferation () and inducing translation initiation factor eIF4B and protein synthesis (; ). p90RSK phosphorylates Max dimerization protein-1 (Mad1) resulting in release of its suppression of Myc and increased proliferation (). p90RSK also regulates cell growth and protein synthesis through modulating mTOR pathway. It has been shown to modulate mTOR by phosphorylating both tuberous sclerosis complex 2 (TSC2) and Raptor (; ). Additionally, RSKs have been shown to interact with c-Fos, an important transcription factor in cell cycle G1 phase (); and phosphorylate p27kip1 to induce cell cycle G1 phase progression (; ).
p90RSK also plays an important role in cell survival, as it has been shown to phosphorylate Bad to decrease apoptosis, and phosphorylate tumor suppressor death-associated protein kinase (DAPK) to cause its inactivation (; ; ). p90RSK has been shown to influence inflammation through phosphorylating NF-κB inhibitors, IκBα and IκBβ (; ; ), and through phosphorylating p38 MAPK to induce M1 macrophage survival (). Moreover, p90RSK phosphorylates downstream substrates filamin A and phosphorylating SH3 domain-containing protein (SH3P2) to induce cell motility and migration (; ). Activated p90RSK phosphorylates Thr368 of sentrin/SUMO-specific protease 2 (SENP2), induces SENP2 nuclear export, and reduces the SENP2 activity, which then increases nuclear ERK5 and p53 SUMOylation, leading to endothelial cell (EC) apoptosis and inflammation (; ; ). In a model of diabetic heart disease, activated p90RSK induces ERK5 Ser496 phosphorylation, inhibits the association of ERK5 and CHIP ubiquitin ligase by binding to ERK5, which decreases the CHIP ubiquitin ligase activity, suppresses inducible cAMP early repressor (ICER) ubiquitination and degradation, and finally promotes cardiac apoptosis (). Activated p90RSK also increases NF-kB activation, VCAM-1 expression, and EC apoptosis through phosphorylating ERK5 Ser496 and regulating its transcriptional activity (). Recently, p90RSK has been shown to bind and phosphorylate the E3 ubiquitin ligase MDM2, which increases the stability of MDM2 leading to its binding and ubiquitinating p53 and cell survival ().
4 Intercellular p90RSK signaling and kidney disease
Normal kidney structure and environment depend on epithelial integrity and interactions between epithelial cells and other kidney cells. Obstructive nephropathy (ON) is the major cause of chronic kidney disease (CKD) leading to renal failure in children () and also happens in adults. However, surgical correction of renal ureteral obstruction does not stop CKD progressing to renal failure in ON patients (; ), suggesting a pathogenic role of intrinsic pathway in obstruction-induced CKD. Both interstitial fibroblasts and tubular epithelial cells play essential roles in ON pathogenesis and progression. In response to injury, epithelial cells, especially proximal tubular epithelial cells, not only initiate inflammatory response by producing proinflammatory chemokines, but also undergo apoptotic death, leading to kidney parenchymal destruction. Structurally, fibroblasts reside in the renal interstitium surrounding the tubules formed by epithelial cells. This proximity facilitates interstitial fibroblast-epithelial communication and interactions that are fundamental in maintaining the integrity of the kidney structure and environment, as well as fine-regulated process of adaptation to pathogenic cues (; ). Our recent work, using a novel fibroblast-specific wildtype p90RSK-transgenic mouse model, has discovered that p90RSK accelerates obstruction-induced renal fibrogenesis by inducing fibroblast-mediated epithelial apoptosis and transdifferentiation through reactive oxygen species (ROS) (; ) and forkhead box class O1 (FOXO1) pathway () (Figure 2). Notably, p90RSK-mediated interactions between inflammatory cells and kidney parenchymal cells remain largely unknown, future investigations are needed for these areas.
FIGURE 2
4.1 Fibroblast p90RSK signaling in tubular epithelial apoptosis
Our recent work has found that fibroblast-specific p90RSK induces tubular epithelial apoptosis and promotes kidney fibrosis (). As shown in Figure 2, p90RSK-overexpressing fibroblasts produce and release excessive H2O2, causing ROS accumulation and β-catenin nuclear translocation in the surrounding epithelial cells. Nuclear β-catenin interacts with transcription factor FOXO1 to promote tubular epithelial apoptosis, leading to kidney structural destruction and eventually fibrosis. These results illuminate a novel mechanism regarding the pivotal role of p90RSK-mediated fibroblast-epithelial communications in CKD development and progression. The juxtaposition of fibroblasts and epithelium facilitates their interactions. Under physiological condition, interstitium-epithelial communication plays a fundamental role in maintaining the integrity of the kidney structure and environment (; ). During wound healing process, renal interstitial cells, including fibroblasts, also provide a supportive environment to promote tubular epithelial regeneration in response to transient injury (). However, persistent pathogenic stimuli will cause extensive activation of signaling mediators, such as p90RSK, and disrupt the delicate healing process, resulting in progressive tissue destruction and loss of function. The recent work shows that p90RSK-transgenic (RSK-Tg) fibroblasts, after chronic obstructive injury, acquire substantially enhanced ability to generate sustained H2O2 that not only induces epithelial injury, but also further triggers the activation of p90RSK (; ) and forms a vicious loop of amplification.
FOXO1, a member of FOXO transcription factor family, controls multiple cellular processes including cell cycle and survival (; ). We have found that obstruction-induced FOXO1 mediates ROS/β-catenin-induced epithelial apoptosis. β-catenin directly binds to the C-terminal of FOXO1 through its armadillo repeats 1 to 8 and activates FOXO1 transcriptional activity (), which subsequently promotes apoptosis by activating pro-apoptotic proteins including BIM and BAD (). In general, epithelial apoptosis is followed by regeneration. However, sustained injuries trigger persistent activation of fibroblast p90RSK, which forms a detrimental environment against tubular regeneration and differentiation, resulting in structural destruction and fibrotic scar formation. Thus, it is likely that p90RSK-mediated fibroblast-epithelial communication plays a decisive role in driving kidney fibrosis.
4.2 Fibroblast p90RSK signaling in tubular epithelial transdifferentiation
In normal kidney, tubules formed by epithelial cells are surrounded by interstitial fibroblasts, supporting epithelial integrity and functions. In response to chronic pathogenic cues, such as oxidative stress, tubular epithelial cells not only undergo apoptotic death, leading to kidney parenchymal destruction, but also contribute to the population of active fibroblasts through a transdifferentiation process known as epithelial-mesenchymal transition (EMT). EMT, is a reversible process involving loss of epithelial integrity indicated by loss of Ecadherin and gain of contractility and mobility by induction of mesenchymal markers including αSMA, that transiently changes epithelial cells into active fibroblasts, i.e. myofibroblasts, with significantly enhanced matrix-producing capability (; ; ). EMT not only plays a fundamental role in embryogenesis and tissue morphogenesis during development, but also is an essential cellular process in wound healing in adults (). When the injury is transient, renal interstitial cells, such as fibroblasts, promote epithelial regeneration to proceed wound healing process (), while epithelial cells further augment the above process by contributing to the population of active fibroblasts with enhanced matrix-producing capability through EMT to help repair and remodeling. However, when pathogenic damage persists, the finely regulated and delicate healing process will be disrupted, leading to progressive tissue destruction and loss of function. Our most recent work demonstrates that p90RSK-overexpressing fibroblasts produce excessive H2O2, causing accumulation of ROS and β-catenin in the surrounding epithelial cells. These β-catenins trigger aberrant epithelial transdifferentiation or EMT through inducing TCF/LET-mediated gene expression. These active fibroblasts derived through EMT process, in turn, produce excessive matrix resulting in diffused scaring formation and renal dysfunction (Figure 2). These studies also highlight the significant role of H2O2 in mediating intercellular p90RSK signaling. Excessive oxidative stress not only induces epithelial β-catenin accumulation and nuclear translocation () causing epithelial damage, but also further activates p90RSK (; ), forming a vicious cycle to amplify renal damage.
4.3 Extracellular vesicles (EVs) and intercellular p90RSK signaling
EVs are a group of nanosized lipid-bound vesicles derived from various cellular origins and are secreted by all cell types and organisms. Although EVs have been subcategorized into several subgroups based on their biogenesis pathway and size, the most common two subsets are exosomes and microvesicles (MVs, also called as ectosomes or microparticles) (; ). The size of exosomes diameter is between 30–150 nm, while that of MVs’ is usually within the range of 50–1,000 nm. Exosomes, containing various biomolecules such as proteins, RNAs, DNAs, lipids, and metabolites, are formed through an endocytic pathway which results in the formation of intraluminal vesicles by inward budding of the multivesicular bodies (). Whereas MVs are formed through outward budding of plasma membrane (). EVs contain various cell type-specific cargos that play a key role in cell-cell communication.
Our recent works demonstrate an important role of H2O2 in mediating intercellular p90RSK signaling between interstitial fibroblasts and tubular epithelial cells. Given the significant role of EVs in cell-cell communication, we have conducted a pilot study to test whether p90RSK-overexpressing fibroblast-derived EVs could be deliverable into co-cultured tubular epithelial cells. Briefly, primary mouse RSK-Tg fibroblasts, as well as their wildtype counterparts (RSK-wt), were labeled by PKH26 red fluorescence, followed by coculture with mouse TKPT tubular epithelial cells for 72 h. Then epithelial cells were extracted for intracellular EVs assay and quantitation by flow cytometry. There were dramatically increased RSK-Tg fibroblasts-derived EVs in TKPT epithelial cells (Figure 3) confirming that EVs derived from RSK-Tg fibroblasts were delivered into cocultured epithelial cells. Thus, EVs may also play an important role in mediating intercellular p90RSK signaling between interstitial fibroblasts and tubular epithelial cells. Further investigations are warranted to determine the responsible EV cargo mediators in p90RSK-mediated fibroblast-epithelial communication.
FIGURE 3
5 Intracellular p90RSK signaling and kidney disease
p90RSK signaling is activated in a mouse model of unilateral ureter obstruction (UUO), a classic CKD model. After UUO injury, immune staining shows that phosphorylation of p90RSK and its upstream signaling such as Erk1/2 is markedly induced in the damaged kidneys. The activation of p90RSK, i.e. phosphorylation of p90RSK, correlates with the severity of kidney fibrosis as indicated by induction of matrix proteins and destroyed kidney structure (). In vitro, kidney cells treated with profibrotic factors, such as tPA and TGF-beta, display increased p90RSK phosphorylation and activation (; ; ). Collectively, these findings directly point to an important role of p90RSK in the initiation and progression of CKD. After obstructive damage, p90RSK is primarily activated in the interstitium of kidney, where abundant resident fibroblasts reside, and plenty infiltrated inflammatory cells accumulate. p90RSK signaling activated within these cells modulates various cellular processes, such as cell death and proliferation, to contribute to the pathogenesis and progression of CKD.
5.1 Kidney fibrosis
Kidney fibrosis is histologically characterized by excessive renal deposition of matrix proteins. Interstitial fibroblasts, as well as their activated form of myofibroblasts, are the primary matrix-producing cells in the kidney. The number of interstitial fibroblasts and myofibroblasts, which is determined by the balance between proliferation and cell death, closely correlates with the severity of tubulointerstitial fibrosis and concomitant decline of kidney function (). We have shown that p90RSK modulates renal fibroblast intracellular signaling to promote renal fibrosis through tilting the balance from cell death to growth to generate substantial amount of kidney interstitial fibroblasts (; ). tPA, after binding to its receptor LRP-1 in renal fibroblasts, induces LRP-1 Tyr4507 phosphorylation and subsequently activates its downstream Erk1/2 and p90RSK pathway. The activated p90RSK, in turn, phosphorylates its downstream substrates, such as GSK-3β and Bad, to induce fibroblast proliferation and survival (; ). GSK-3β exists in a constitutively active form and inhibits cyclinD1 and other downstream mediators through ubiquitination and proteasomal degradation. p90RSK phosphorylates and inactivates GSK-3β, resulting in cyclin D1 stabilization and accumulation, which facilitates fibroblasts entry into the cell cycle S phase and induces cell proliferation (). Bad is a pro-death member of the Bcl-2 protein family. As a downstream substrate of p90RSK, Bad phosphorylation by p90RSK leads to its inactivation and blockage of its entrance into mitochondria after apoptotic injury, and suppression of cytochrome C releasing into cytosol. Decreased cytosol cytochrome C reduces the cleavage and activation of the caspases, resulting in decreased cell death and increased cell survival (). Thus, in tPA-mediated profibrotic pathway, p90RSK activation not only promotes fibroblast survival through p90RSK/Bad/cytochrome C pathway; but also induces fibroblast proliferation through p90RSK/GSK-3β/cyclin D1 signaling (; ), which together lead to fibroblast accumulation in the diseased kidneys resulting in progressive renal fibrosis (Figure 4).
FIGURE 4
5.2 Kidney inflammation
Macrophage plays a critical role in kidney inflammation and its accumulation is one of the histological hallmarks of CKD. In diseased conditions, macrophages, including resident and bone marrow monocyte-derived macrophages (), are differentiated into a spectrum between two distinct subsets: classically activated M1 and alternatively activated M2 macrophages. M1 macrophages are usually induced by exposure to IFN-γ or lipopolysaccharide (LPS), after which, these macrophages not only produce nitric oxide or reactive oxygen intermediates to protect against bacteria or viral pathogens but also produce abundant proinflammatory cytokines to initiate immune response, recruit more inflammatory cells and exaggerate damage. In contrast, after exposure to IL4, IL10 or IL13, M2 macrophages help to resolve inflammation and promote wound healing and tissue repair (; ; ). Resting macrophages (M0) have a finite lifespan but become resistant to apoptosis in response to injury. Our previous work has shown that p90RSK, after phosphorylated and activated by tPA, protects macrophage against apoptosis induced by hydrogen peroxide (H2O2) or staurosporine indicating that p90RSK mediates damage-triggered apoptosis resistance. Intriguingly, activated p90RSK only protects resting M0 macrophages and classically activated M1 macrophages, but not the alternative activated M2 macrophages, against H2O2 or staurosporine-induced apoptosis (). In obstruction-induced fibrotic kidneys, increased p90RSK activation correlates to the severer disease condition such as increased extracellular matrix (ECM) accumulation, enhanced M1 macrophage infiltration and more profound proinflammatory cytokine expression (; ). There are three known MAPK members: Erk/12, the C-jun N-terminal kinases (JNKs), and the p38 (). It is known that p38 functions parallel to Erk1/2 MAPK, and usually promotes apoptosis (). However, we have discovered that p38 is a novel downstream substrate of macrophage intracellular p90RSK mediating its cytoprotective effects (). Thus, p90RSK promotes survival and accumulation of macrophages, especially the M1 macrophages, through phosphorylating its intracellular p38 MAPK pathway. These increased M1 macrophages, in turn, produce a panoply of proinflammatory cytokines and chemokines, resulting in increased inflammatory cell recruitment, severer inflammatory response, and excessive renal damage (Figure 4).
5.3 Diabetic nephropathy (DN)
DN is histologically characterized by thickened tubular basal (TBM) and glomerular basement (GBM) membranes, excessive ECM deposition and progressive mesangial hypertrophy. DN is one of the leading causes of end stage renal disease (). Around 30%–40% of the total glomerular cell population are mesangial cells, which play an important role in maintaining glomerular integrity (). Mesangial hypertrophy is characterized by excessive mesangial matrix deposition, which eventually leads to glomerulosclerosis, if not under control. TGF-β is the most prominent growth factor mediating the hypertrophic effect of hyperglycemia in DN (). TGF-β has been shown to induce Erk1/2 and p90RSK activation in mesangial cells. Activated p90RSK phosphorylates and inactivates eukaryotic elongation factor2 (eEF2) kinase, leading to decreased eEF2 phosphorylation and augmented activity. Activation of eEF2 promotes matrix production and deposition in the mesangial region causing hypertrophy. Mesangial intracellular p90RSK is indispensable to TGF-β-induced mesangial hypertrophy because dominant-negative p90RSK abolishes the effects of TGF-β () (Figure 4).
Oxidative stress plays an important role in DN pathogenesis and progression. In monocytes/macrophages treated with various combination antiretroviral therapies (cARTs), p90RSK is activated, which then phosphorylates Ser496 of ERK5, inhibits NRF2-ARE activity, reduces the telomere length and decreases antioxidant expression, resulting in increased sensitivity of monocytes/macrophages to oxidative stress. Activated macrophage intracellular p90RSK signaling cascade also induces the expression of pro-inflammatory genes such as TNFα, and decreases the expression of efferocytosis-related genes, such as Gas6, causing inflammation, matrix deposition, and sclerosis () (Figure 4).
5.4 Glomerular diseases
Most glomerular diseases are presented with proteinuria. In physiological condition, the healthy glomerular filtration barrier, consisting of endothelium, GBM, and podocytes, only allows the passthrough of metabolic wastes but not proteins larger than albumin from plasma inside the glomerular capillaries into resultant urine within Bowman’s capsule. Podocytes cover the outer surface of the GBM, and their long-interdigitated foot processes form filtration slits and are critical for the integrity of glomerular filtration barrier. As terminally differentiated cells, podocytes cannot regenerate when injured. In a puromycin aminonucleoside (PAN)-induced injury model, podocytes undergo apoptosis and detach from GBM, leading to glomerular filtration barrier integrity disruption and proteinuria (). It has been found that calcimimetic R-568 induces Erk1/2-mediated p90RSK/CREB signaling cascade, alleviates PAN-induced proteinuria, attenuates glomerulosclerosis, and improves GFR. p90RSK has been shown to mediate protective effect of R568 through activating the pro-survival signaling of Bad and Bcl-xl and suppressing PAN-induced podocyte apoptosis and damage ().
5.5 Other kidney diseases
Epithelial intracellular p90RSK signaling has also been implicated in other kidney diseases including hypocitraturia, kidney stone, virus-induced kidney injury, as well as renal cell carcinoma (RCC). p90RSK has been shown to mediate IL11-induced tubular epithelial dedifferentiation (). In a mouse model of bone metastasis of RCC, intracardiac injection of calcium-sensing receptor (CaSR)-transfected RCC cells demonstrates an increased rate of bone metastasis. Calcium-induced SHC, Akt, Erk, p90RSK and JNK in CaSR-transfected RCC cells have been associated with enhanced adhesion to endothelial cells and ECM components, as well as calcium-induced chemotactic cell migration and proliferation (). Intriguingly, although p90RSK signaling is activated in a genetic PKD1 inaction model of polycystic kidney disease (PKD), p90RSK inhibition has little effect on the cyst growth (). Thus, the roles of intracellular p90RSK signaling in some kidney diseases are context dependent.
Acidified media has been shown to activate the citrate transporter NaDC-1 through Raf1, ERK1/2 and p90RSK signaling in the opossum kidney proximal tubule cells, suggesting an important role of p90RSK signaling in hypocitraturia and kidney stone formation (). It has also been found that severe acute respiratory syndrome (SARS)-coronavirus (CoV) infection induces p38 MAPK-mediated Ser380 phosphorylation of p90RSK but not through Erk1/2-induced Thr573 phosphorylation in kidney epithelial cells, indicating a role of epithelial intracellular p90RSK signaling in virus-induced kidney damage (). During the recovery phase after acute kidney injury, surviving epithelial cells de-differentiate, migrate to the injury site, proliferate and then re-differentiate to establish epithelial polarity and restore kidney function (). HGF, PMA and EGF-induced p90RSK signaling is implied in the motility response of kidney epithelial cells (), indicating a critical role of epithelial intracellular p90RSK signaling in mediating kidney repair and regeneration after acute injury. Most recently, activated epithelial intracellular p90RSK has been shown to mediate anisodamine-induced renal recovery after acute ischemia/reperfusion injury ().
6 Conclusion and future perspectives
Emerging evidences support an essential role of p90RSK in mediating a complex intercellular and intracellular signaling network to modulate diverse cellular processes to initiate various progressive kidney diseases. Notably, the roles of p90RSK in kidney diseases are context dependent, because its induction is an initial finely regulated wound-healing response until the sustained damage-caused chaotic signal and cellular reactions leading to aberrant activation of p90RSK signal cascades and subsequent tissue destruction and scar formation. Currently, the role of p90RSK in kidney disease remains largely unknown. Future investigations should not only further clarify its renal pathogenic roles but also focus on its roles in mediating interactions between inflammatory cells and renal parenchymal cells during CKD pathogenesis and progression, as well as the development of p90RSK-specific treatment.
Statements
Author contributions
LL: Conceptualization, Data curation, Resources, Writing – review and editing, Supervision, Funding acquisition, Project administration, Formal Analysis, Investigation, Methodology, Writing – original draft, Validation. KH: Methodology, Formal Analysis, Supervision, Project administration, Data curation, Resources, Writing – review and editing, Writing – original draft, Investigation, Conceptualization, Funding acquisition, Validation.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. LL is supported by American Heart Association Career Development Award (941281). KH is supported by the Pennsylvania Department of Health Tobacco CURE Funds (4100085731).
Acknowledgments
We thank Chaowen Shi for technical assistance in EV evaluation.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbeJ. I.SandhuU. G.HoangN. M.ThangamM.Quintana-QuezadaR. A.FujiwaraK.et al (2017). Coordination of cellular localization-dependent effects of sumoylation in regulating cardiovascular and neurological diseases. Adv. Exp. Med. Biol.963, 337–358. 10.1007/978-3-319-50044-7_20
2
AcloqueH.AdamsM. S.FishwickK.Bronner-FraserM.NietoM. A. (2009). Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest119 (6), 1438–1449. 10.1172/JCI38019
3
AnjumR.BlenisJ. (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol.9 (10), 747–758. 10.1038/nrm2509
4
AnjumR.RouxP. P.BallifB. A.GygiS. P.BlenisJ. (2005). The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr. Biol.15 (19), 1762–1767. 10.1016/j.cub.2005.08.050
5
ArangoD. G.DescoteauxA. (2014). Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol.5, 491. 10.3389/fimmu.2014.00491
6
BerumenS. G.BunnK. E.PuaH. H.RafatM. (2021). Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. Cell Commun. Signal19 (1), 104. 10.1186/s12964-021-00787-y
7
BjorbaekC.ZhaoY.MollerD. E. (1995). Divergent functional roles for p90rsk kinase domains. J. Biol. Chem.270 (32), 18848–18852. 10.1074/jbc.270.32.18848
8
BonniA.BrunetA.WestA. E.DattaS. R.TakasuM. A.GreenbergM. E. (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science286 (5443), 1358–1362. 10.1126/science.286.5443.1358
9
BorgesF. T.MeloS. A.OzdemirB. C.KatoN.RevueltaI.MillerC. A.et al (2013). TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc. Nephrol.24 (3), 385–392. 10.1681/ASN.2012101031
10
CarriereA.CargnelloM.JulienL. A.GaoH.BonneilE.ThibaultP.et al (2008b). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr. Biol.18 (17), 1269–1277. 10.1016/j.cub.2008.07.078
11
CarriereA.RayH.BlenisJ.RouxP. P. (2008a). The RSK factors of activating the Ras/MAPK signaling cascade. Front. Biosci.13, 4258–4275. 10.2741/3003
12
ChenR. H.AbateC.BlenisJ. (1993). Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc. Natl. Acad. Sci. U. S. A.90 (23), 10952–10956. 10.1073/pnas.90.23.10952
13
DalbyK. N.MorriceN.CaudwellF. B.AvruchJ.CohenP. (1998). Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J. Biol. Chem.273 (3), 1496–1505. 10.1074/jbc.273.3.1496
14
DasF.Ghosh-ChoudhuryN.KasinathB. S.ChoudhuryG. G. (2010). TGFβ enforces activation of eukaryotic elongation factor-2 (eEF2) via inactivation of eEF2 kinase by p90 ribosomal S6 kinase (p90Rsk) to induce mesangial cell hypertrophy. FEBS Lett.584 (19), 4268–4272. 10.1016/j.febslet.2010.09.010
15
DongreA.WeinbergR. A. (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol.20 (2), 69–84. 10.1038/s41580-018-0080-4
16
EijkelenboomA.BurgeringB. M. (2013). FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. Mol. Cell Biol.14 (2), 83–97. 10.1038/nrm3507
17
El-AchkarT. M.DagherP. C. (2015). Tubular cross talk in acute kidney injury: a story of sense and sensibility. Am. J. Physiol. Ren. Physiol.308 (12), F1317–F1323. 10.1152/ajprenal.00030.2015
18
EriksonE.MallerJ. L. (1985). A protein kinase from Xenopus eggs specific for ribosomal protein S6. Proc. Natl. Acad. Sci. U. S. A.82 (3), 742–746. 10.1073/pnas.82.3.742
19
EssersM. A.de Vries-SmitsL. M.BarkerN.PoldermanP. E.BurgeringB. M.KorswagenH. C. (2005). Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science308 (5725), 1181–1184. 10.1126/science.1109083
20
FisherT. L.BlenisJ. (1996). Evidence for two catalytically active kinase domains in pp90rsk. Mol. Cell Biol.16 (3), 1212–1219. 10.1128/mcb.16.3.1212
21
FreesS.BreukschI.HaberT.BauerH. K.Chavez-MunozC.RavenP.et al (2018). Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget9 (21), 15766–15779. 10.18632/oncotarget.24607
22
FrodinM.JensenC. J.MerienneK.GammeltoftS. (2000). A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J.19 (12), 2924–2934. 10.1093/emboj/19.12.2924
23
FujitaN.SatoS.TsuruoT. (2003). Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem.278 (49), 49254–49260. 10.1074/jbc.M306614200
24
GhodaL.LinX.GreeneW. C. (1997). The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J. Biol. Chem.272 (34), 21281–21288. 10.1074/jbc.272.34.21281
25
HeoK. S.LeN. T.CushmanH. J.GiancursioC. J.ChangE.WooC. H.et al (2015). Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J. Clin. Invest125 (3), 1299–1310. 10.1172/JCI76453
26
HuK.LinL.TanX.YangJ.BuG.MarsW. M.et al (2008). tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J. Am. Soc. Nephrol.19 (3), 503–514. 10.1681/ASN.2007030300
27
JensenC. J.BuchM. B.KragT. O.HemmingsB. A.GammeltoftS.FrodinM. (1999). 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. J. Biol. Chem.274 (38), 27168–27176. 10.1074/jbc.274.38.27168
28
KalluriR.McAndrewsK. M. (2023). The role of extracellular vesicles in cancer. Cell186 (8), 1610–1626. 10.1016/j.cell.2023.03.010
29
KangS.DongS.GuT. L.GuoA.CohenM. S.LonialS.et al (2007). FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell12 (3), 201–214. 10.1016/j.ccr.2007.08.003
30
LamE. W.BrosensJ. J.GomesA. R.KooC. Y. (2013). Forkhead box proteins: tuning forks for transcriptional harmony. Nat. Rev. Cancer13 (7), 482–495. 10.1038/nrc3539
31
LazarovT.Juarez-CarrenoS.CoxN.GeissmannF. (2023). Physiology and diseases of tissue-resident macrophages. Nature618 (7966), 698–707. 10.1038/s41586-023-06002-x
32
LeN. T.SandhuU. G.Quintana-QuezadaR. A.HoangN. M.FujiwaraK.AbeJ. I. (2017). Flow signaling and atherosclerosis. Cell Mol. Life Sci.74 (10), 1835–1858. 10.1007/s00018-016-2442-4
33
LeN. T.TakeiY.ShishidoT.WooC. H.ChangE.HeoK. S.et al (2012). p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ. Res.110 (4), 536–550. 10.1161/CIRCRESAHA.111.254730
34
LinL.BuG.MarsW. M.ReevesW. B.TanakaS.HuK. (2010). tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway. Am. J. Pathol.177 (4), 1687–1696. 10.2353/ajpath.2010.100213
35
LinL.JinY.HuK. (2015). Tissue-type plasminogen activator (tPA) promotes M1 macrophage survival through p90 ribosomal S6 kinase (RSK) and p38 mitogen-activated protein kinase (MAPK) pathway. J. Biol. Chem.290 (12), 7910–7917. 10.1074/jbc.M114.599688
36
LinL.ShiC.SunZ.LeN. T.AbeJ. I.HuK. (2019b). The Ser/Thr kinase p90RSK promotes kidney fibrosis by modulating fibroblast-epithelial crosstalk. J. Biol. Chem.294 (25), 9901–9910. 10.1074/jbc.RA119.007904
37
LinL.WhiteS. A.HuK. (2019a). Role of p90RSK in kidney and other diseases. Int. J. Mol. Sci.20 (4), 972. 10.3390/ijms20040972
38
LinL.WuC.HuK. (2012). Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J. Am. Soc. Nephrol.23 (8), 1329–1338. 10.1681/ASN.2011111123
39
MacKenzieS. J.BaillieG. S.McPheeI.BolgerG. B.HouslayM. D. (2000). ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J. Biol. Chem.275 (22), 16609–16617. 10.1074/jbc.275.22.16609
40
MahimainathanL.DasF.VenkatesanB.ChoudhuryG. G. (2006). Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes55 (7), 2115–2125. 10.2337/db05-1326
41
MaiettaI.Del PeschioF.BuonocoreP.ViscusiE.LaudatiS.IannaciG.et al (2022). p90RSK regulates p53 pathway by MDM2 phosphorylation in thyroid tumors. Cancers (Basel)15 (1), 121. 10.3390/cancers15010121
42
McLeodD. J.ChingC. B.SebastiaoY. V.GreenbergJ. H.FurthS. L.McHughK. M.et al (2018). Common clinical markers predict end-stage renal disease in children with obstructive uropathy. Pediatr. Nephrol.34, 443–448. 10.1007/s00467-018-4107-z
43
MizutaniT.FukushiS.SaijoM.KuraneI.MorikawaS. (2006). Regulation of p90RSK phosphorylation by SARS-CoV infection in Vero E6 cells. FEBS Lett.580 (5), 1417–1424. 10.1016/j.febslet.2006.01.066
44
MosserD. M. (2003). The many faces of macrophage activation. J. Leukoc. Biol.73 (2), 209–212. 10.1189/jlb.0602325
45
MunizJ. R. C.ElkinsJ. M.WangJ.UgochukwuE.SalahE.KingO.et al (2009). Crystal structure of the human ribosomal protein S6 kinase. 10.2210/pdb2WNT/pdb
46
NiW. J.TangL. Q.WeiW. (2015). Research progress in signalling pathway in diabetic nephropathy. Diabetes Metab. Res. Rev.31 (3), 221–233. 10.1002/dmrr.2568
47
NietoM. A.HuangR. Y.JacksonR. A.ThieryJ. P. (2016). Emt: 2016. Cell166 (1), 21–45. 10.1016/j.cell.2016.06.028
48
OhJ.BeckmannJ.BlochJ.HettgenV.MuellerJ.LiL.et al (2011). Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int.80 (5), 483–492. 10.1038/ki.2011.105
49
RamanM.ChenW.CobbM. H. (2007). Differential regulation and properties of MAPKs. Oncogene26 (22), 3100–3112. 10.1038/sj.onc.1210392
50
RomeoY.RouxP. P. (2011). Paving the way for targeting RSK in cancer. Expert Opin. Ther. Targets15 (1), 5–9. 10.1517/14728222.2010.531014
51
RothK. S.KooH. P.SpottswoodS. E.ChanJ. C. (2002). Obstructive uropathy: an important cause of chronic renal failure in children. Clin. Pediatr. (Phila).41 (5), 309–314. 10.1177/000992280204100503
52
RouxP. P.BallifB. A.AnjumR.GygiS. P.BlenisJ. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U. S. A.101 (37), 13489–13494. 10.1073/pnas.0405659101
53
RouxP. P.RichardsS. A.BlenisJ. (2003). Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol. Cell Biol.23 (14), 4796–4804. 10.1128/mcb.23.14.4796-4804.2003
54
SauerH.KlimmB.HeschelerJ.WartenbergM. (2001). Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Faseb J.15 (13), 2539–2541. 10.1096/fj.01-0360fje
55
SchiesslI. M.GrillA.FremterK.SteppanD.HellmuthM. K.CastropH. (2018). Renal interstitial platelet-derived growth factor receptor-beta cells support proximal tubular regeneration. J. Am. Soc. Nephrol.29 (5), 1383–1396. 10.1681/ASN.2017101069
56
SchoutenG. J.VertegaalA. C.WhitesideS. T.IsraelA.ToebesM.DorsmanJ. C.et al (1997). IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J.16 (11), 3133–3144. 10.1093/emboj/16.11.3133
57
ScindiaY. M.DeshmukhU. S.BagavantH. (2010). Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv. Drug Deliv. Rev.62 (14), 1337–1343. 10.1016/j.addr.2010.08.011
58
ShiC.LinL.HuK. (2023). Fibroblast p90RSK induces epithelial transdifferentiation through oxidative stress-mediated beta-catenin pathway. Clin. Transl. Med.13 (1), e1128. 10.1002/ctm2.1128
59
ShibazakiS.YuZ.NishioS.TianX.ThomsonR. B.MitobeM.et al (2008). Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet.17 (11), 1505–1516. 10.1093/hmg/ddn039
60
SinghM. V.KotlaS.LeN. T.KoK. A.HeoK. S.WangY.et al (2018). Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative stress in HIV(+) individuals: implications for atherogenesis. Circulation139, 1199–1216. 10.1161/CIRCULATIONAHA.118.036232
61
SusnikN.MelkA.SchmittR. (2015). Cell aging and kidney repair. Cell Cycle14 (22), 3521–3522. 10.1080/15384101.2015.1032636
62
SutherlandC.AlterioJ.CampbellD. G.Le BourdellesB.MalletJ.HaavikJ.et al (1993). Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. Eur. J. Biochem.217 (2), 715–722. 10.1111/j.1432-1033.1993.tb18297.x
63
TakeishiY.AbeJ.LeeJ. D.KawakatsuH.WalshR. A.BerkB. C. (1999). Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused Guinea pig hearts. Circ. Res.85 (12), 1164–1172. 10.1161/01.res.85.12.1164
64
TanimuraS.ChataniY.HoshinoR.SatoM.WatanabeS.KataokaT.et al (1998). Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene17 (1), 57–65. 10.1038/sj.onc.1201905
65
TanimuraS.HashizumeJ.KurosakiY.SeiK.GotohA.OhtakeR.et al (2011). SH3P2 is a negative regulator of cell motility whose function is inhibited by ribosomal S6 kinase-mediated phosphorylation. Genes cells.16 (5), 514–526. 10.1111/j.1365-2443.2011.01503.x
66
ThorntonT. M.RinconM. (2009). Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int. J. Biol. Sci.5 (1), 44–51. 10.7150/ijbs.5.44
67
VikT. A.RyderJ. W. (1997). Identification of serine 380 as the major site of autophosphorylation of Xenopus pp90rsk. Biochem. Biophys. Res. Commun.235 (2), 398–402. 10.1006/bbrc.1997.6794
68
VuH. T.KotlaS.KoK. A.FujiiY.TaoY.MedinaJ.et al (2018). Ionizing radiation induces endothelial inflammation and apoptosis via p90RSK-mediated ERK5 S496 phosphorylation. Front. Cardiovasc Med.5, 23. 10.3389/fcvm.2018.00023
69
WangX.JanmaatM.BeugnetA.PaulinF. E.ProudC. G. (2002). Evidence that the dephosphorylation of Ser(535) in the epsilon-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for the activation of eIF2B by insulin. Biochem. J.367 (Pt 2), 475–481. 10.1042/BJ20020677
70
WarshawB. L.EdelbrockH. H.EttengerR. B.MalekzadehM. H.PennisiA. J.UittenbogaartC. H.et al (1982). Progression to end-stage renal disease in children with obstructive uropathy. J. Pediatr.100 (2), 183–187. 10.1016/s0022-3476(82)80631-8
71
WidjajaA. A.ViswanathanS.ShekeranS. G.AdamiE.LimW. W.ChothaniS.et al (2022). Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease. Nat. Commun.13 (1), 7497. 10.1038/s41467-022-35306-1
72
WooM. S.OhtaY.RabinovitzI.StosselT. P.BlenisJ. (2004). Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol. Cell Biol.24 (7), 3025–3035. 10.1128/mcb.24.7.3025-3035.2004
73
XuS.BayatH.HouX.JiangB. (2006). Ribosomal S6 kinase-1 modulates interleukin-1beta-induced persistent activation of NF-kappaB through phosphorylation of IkappaBbeta. Am. J. Physiol. Cell Physiol.291 (6), C1336–C1345. 10.1152/ajpcell.00552.2005
74
YangW. S.CalivaM. J.KhadkaV. S.TiirikainenM.MatterM. L.DengY.et al (2022). RSK1 and RSK2 serine/threonine kinases regulate different transcription programs in cancer. Front. Cell Dev. Biol.10, 1015665. 10.3389/fcell.2022.1015665
75
YntemaH. G.van den HelmB.KissingJ.van DuijnhovenG.PoppelaarsF.ChellyJ.et al (1999). A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation. Genomics62 (3), 332–343. 10.1006/geno.1999.6004
76
ZacchiaM.TianX.ZonaE.AlpernR. J.PreisigP. A. (2018). Acid stimulation of the citrate transporter NaDC-1 requires Pyk2 and ERK1/2 signaling pathways. J. Am. Soc. Nephrol.29 (6), 1720–1730. 10.1681/ASN.2017121268
77
ZaruR.RonkinaN.GaestelM.ArthurJ. S.WattsC. (2007). The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat. Immunol.8 (11), 1227–1235. 10.1038/ni1517
78
ZeniouM.DingT.TrivierE.HanauerA. (2002). Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin-Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning. Hum. Mol. Genet.11 (23), 2929–2940. 10.1093/hmg/11.23.2929
79
ZhangS.XuX.HuangY.SunS.JinC.JiH.et al (2021). Anisodamine ameliorates ischemia/reperfusion-induced renal injury in rats through activation of the extracellular signal-regulated kinase (ERK) pathway and anti-apoptotic effect. Pharmazie76 (5), 220–224. 10.1691/ph.2021.1302
80
ZhangX.TangN.HaddenT. J.RishiA. K. (2011). Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta1813 (11), 1978–1986. 10.1016/j.bbamcr.2011.03.010
81
ZhaoX.HwangD. Y.KaoH. Y. (2018). The role of glucocorticoid receptors in podocytes and nephrotic syndrome. Nucl. Recept. Res.5, 101323. 10.11131/2018/101323
82
ZhuJ.BlenisJ.YuanJ. (2008). Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl. Acad. Sci. U. S. A.105 (18), 6584–6589. 10.1073/pnas.0802785105
Summary
Keywords
p90RSK, intracellular signaling, intercellular signaling, extracellular vesicles, kidney diseases
Citation
Lin L and Hu K (2025) p90RSK modulates inter-and intracellular signaling in kidney diseases. Front. Cell Dev. Biol. 13:1593914. doi: 10.3389/fcell.2025.1593914
Received
14 March 2025
Accepted
30 May 2025
Published
05 June 2025
Volume
13 - 2025
Edited by
David A. Tumbarello, University of Southampton, United Kingdom
Reviewed by
Shristi Pawnikar, Deep Apple Therapeutics, Inc., United States
Valentina De Falco, National Research Council (CNR), Italy
Updates
Copyright
© 2025 Lin and Hu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ling Lin, llin1@pennstatehealth.psu.edu; Kebin Hu, kebinhu@pennstatehealth.psu.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.